SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Continued to advance the development of CLD-401 towards the clinic - Presented new CLD-401 data an

CLDI

Related stories